High Specialty Drug Copays In Exchange Plans Spark Worry Among Stakeholders
Executive Summary
At the PhRMA annual meeting, drug company executives and patient advocates expressed concern that the high cost-sharing requirements for specialty drugs seen in some exchange plans may also be adopted in the broader commercial insurance market.